This inventor holds 3 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignees: Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch, Max-Delbruck-Centrum Fur Molekulare Medizin in Der Helmholtz-Gemeinschaft, Max-Delbrück-Centrum Für Molekulare Medizin in Der Helmholtz-Geminschaft. Active years: 2015-2025.
Company Filing History:
1 out of 6 
1 out of 23 
1 out of 1 Years Active: 2015-2025
Title: Elisa Kieback: Innovator in Chimeric Antigen Receptor Technology
Introduction
Elisa Kieback is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of immunology, particularly in the development of chimeric antigen receptors (CAR) and CAR-T cell therapies. With a total of 3 patents, her work focuses on innovative solutions for treating diseases associated with pathogenic B cells.
Latest Patents
Kieback's latest patents include groundbreaking inventions related to chimeric antigen receptors and CAR-T cells that specifically bind to B Cell Maturation Antigen (BCMA). One of her notable inventions describes an isolated chimeric antigen receptor polypeptide that comprises an extracellular antigen-binding domain. This domain includes an antibody or antibody fragment that binds to BCMA, particularly targeting an epitope consisting of amino acids from residues 13 to 32 of the N-terminus of human BCMA. Additionally, her patents disclose a nucleic acid molecule encoding the CAR, genetically modified immune cells expressing the CAR, and their application in treating medical disorders linked to pathogenic B cells, such as multiple myeloma and non-Hodgkin's lymphoma.
Career Highlights
Elisa Kieback has worked at prestigious institutions, including the Max Delbrück Center for Molecular Medicine in Berlin-Buch and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association. Her research has significantly advanced the understanding and treatment of various B cell-related diseases.
Collaborations
Throughout her career, Kieback has collaborated with esteemed colleagues, including Wolfgang Uckert and Armin Rehm. These partnerships have further enriched her research and contributed to her innovative work in the field.
Conclusion
Elisa Kieback is a trailblazer in the development of CAR technology, with her patents paving the way for new therapeutic approaches to combat diseases associated with B cells. Her contributions continue to influence the field of immunology and offer hope for patients suffering from complex medical conditions.